logo
USAID cuts could send global health into chaos

USAID cuts could send global health into chaos

Yahoo02-03-2025

The Trump administration's decision to end almost all foreign aid spending from the United States Agency for International Development (USAID) is poised to plunge global health into chaos.
The contract terminations announced Wednesday will end grants for HIV treatments and prevention, tuberculosis, polio, malaria, Ebola and numerous other diseases and conditions. Nutrition assistance programs for infants in developing countries have also been halted, organizations said.
Nearly 5,800 projects funded by USAID have been terminated, ending the hope that contracts previously frozen might have been restarted.
'This reckless and unilateral move will cost millions of lives around the world,' said the Global Health Council, an alliance of nonprofit organizations and companies that receive U.S. foreign aid funding, in a statement.
'With the stroke of a pen, the U.S. government has gutted decades of progress in global health, development, and humanitarian aid — without due process, transparency, or good faith consideration of the consequences,' the council said.
The Global Health Council is one of the nonprofits that have challenged a freeze on foreign aid.
Shortly after taking office, the Trump administration suspended nearly all foreign assistance, saying the funds needed to undergo a 90-day review to ensure compliance with the administration's policies.
The freeze led to thousands of humanitarian workers losing their jobs and life-threatening delays in food and medicine to impoverished areas around the world.
A few days later, the State Department issued stop work orders on foreign assistance funded by or through the State Department and USAID, including existing awards. The stop-work orders came without warning, sowing immediate chaos and confusion.
The State Department then issued waivers to allow certain 'lifesaving' programs, including the President's Emergency Plan for AIDS Relief (PEPFAR), to continue. But the waivers were unevenly applied, and organizations granted waivers said they still weren't being paid.
International health groups said they were under the impression the waivers would continue to apply through the 90-day review period.
'The chaos and confusion of the last four weeks we thought had reached a fever pitch but what happened [Wednesday] night takes this to a new dimension. Every project imaginable in HIV, tuberculosis, malaria, nutritional support, has now been terminated,' said Mitchell Warren, executive director of AVAC, an international nonprofit focused on HIV prevention and one of the plaintiffs in the effort to unfreeze funding.
'The only strategy the administration seems to have is to sow chaos and confusion. There's no effort to look at what aligns with foreign policy, diplomacy, partnerships. And no strategy to prepare for public health threats,' Warren said.
But on Wednesday night, the administration said it had concluded a 'a good-faith, individualized assessment' of USAID's 6,300 grants in less than a month.
'Secretary [of State Marco] Rubio has now made a final decision with respect to each award, on an individualized basis, affirmatively electing to either retain the award or terminate it pursuant to the terms of the instrument or independent legal authority as inconsistent with the national interests and foreign policy of the United States,' the administration said in a court filing.
The State Department has said the agency spared critical awards for lifesaving medical treatment, including those that had been operating under a waiver from the earlier funding freeze, but health groups say that is not the case.
For instance, the Elizabeth Glaser Pediatric AIDS Foundation said three of its primary USAID agreements, which had received approval to resume limited work under the State Department's waiver for lifesaving work, were terminated.
The projects supported more than 350,000 people on HIV treatment, including nearly 10,000 children and more than 10,000 HIV-positive pregnant people in Lesotho, Eswatini, and Tanzania.
The International Rescue Committee (IRC) said 46 of its USAID and State Department programs were canceled, including funding for operating nutrition assistance centers, which help severely malnourished children. Those had been operating under a waiver.
The Joint United Nations HIV/AIDS program said its U.S. government funding was also terminated.
Global health experts said the effects of the cuts will be disastrous, both in terms of health and for how the U.S. is seen throughout the rest of the world.
If a person with HIV stops taking the medication, the virus is no longer suppressed and can multiply, leading to weakened immune systems, illness and then potential spread to others.
For malaria, the cuts mean programs that supplied mosquito nets for cribs won't continue, which means fewer babies protected from malaria. That increases malaria infections, which then can increase deaths.
'It's just a cascading effect on almost every level that ultimately leads to more people being ill, more people dying, and ultimately more costs associated with running these programs and caring for these people,' said Jirair Ratevosian, a fellow at Duke University's Global Health Institute who worked as a chief of staff for the PEPFAR program.
'So it's counterintuitive to what we're trying to do.'
Jen Kates, a senior vice president and director of the Global Health & HIV Policy Program at KFF, said the terminations could set back years of health progress that the U.S. and others have been working toward in developing countries.
'The U.S., frankly, has been one of the main forces behind health achievements in low- and middle-income countries. So a lot of money was provided to make these gains, and they could be set back,' Kates said. 'The extent of the damage is not known yet, but I think in a lot of cases it might be hard to recover easily, even with the replacement funds at some point in the future.'
Jocelyn Wyatt, CEO of the aid group Alight, said she had to terminate programs for millions of displaced people in Sudan, Somalia and South Sudan.
Wyatt said Alight was the largest health provider in Sudan, serving 2.1 million people. They operated under a waiver during the earlier funding freeze, but this week had to close 33 health clinics in the country.
In Somalia, the group had to close 13 health centers, as well as a mobile clinic. In Sudan, it had to stop water and sanitation services and close three camps for displaced people and refugees.
'We're working in very remote regions. Humanitarian assistance was already very scarce. There were not a lot of services before, and now there's none,' Wyatt said. 'These are lifesaving services. There's no alternative, and people will die.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HIV: Supercharged Vaccine Could Protect Well With Just One Dose
HIV: Supercharged Vaccine Could Protect Well With Just One Dose

Newsweek

timean hour ago

  • Newsweek

HIV: Supercharged Vaccine Could Protect Well With Just One Dose

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Center, the vaccine includes two "adjuvants"—materials that help stimulate the immune system response. In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all. This was because the vaccine accumulated in the mice's lymph nodes and remained there for a month—giving their immune systems more time to build up antibodies against HIV. "What's potentially powerful about this approach is that you can achieve long-term exposures based on a combination of adjuvants that are already reasonably well-understood, so it doesn't require a different technology," said paper author and MIT chemical engineer professor J. Christopher Love in a statement. And, the researchers said, the same approach could be used to create one-shot-only vaccines against other diseases, including COVID-19 and influenza. A man receives a vaccination. A man receives a vaccination. Rani Nurlaela Desandi/iStock / Getty Images Plus Most vaccines administered today are accompanied by adjuvants to help make them more effective. One often used with protein-based vaccines—such as given against hepatitis A and B—is "alum," short for "aluminum hydroxide." Alum activates the body's innate immune response, helping it to form a stronger memory of the vaccine antigen in case of a real infection. The new HIV vaccine combines alum with a nanoparticle known as SMNP, which itself combines the FDA-approved, naturally derived adjacent saponin with an inflammation-promoting molecule. In their study, the researchers found that the SMNP–alum combination helped the HIV protein in their vaccine both penetrate the protective layer of cells surrounding the lymph nodes without being broken down, as well as stay intact in the nodes for up to 28 days. The lymph nodes are where protective "B cells" are exposed to antigens—the substances that the body uses to recognize a given infection—and learn to produce the antibodies to fight back. Vaccine antigens (pink) concentrate in B cell follicles (cyan) Vaccine antigens (pink) concentrate in B cell follicles (cyan) MIT "As a result, the B cells that are cycling in the lymph nodes are constantly being exposed to the antigen over that [up to 28 day] time period—and they get the chance to refine their solution to the antigen," Love explained. He added: "When you think about the immune system sampling all of the possible solutions, the more chances we give it to identify an effective solution, the better." When the researchers analyzed the RNA of the B cells from the vaccinated mice, they found that those who had received both adjuvants had produced a more diverse array of B Cells and antibodies than the other rodents. In fact, those who received the dual-adjuvant vaccine produced more than twice as many unique B cells than those mice who received a single-adjuvant vaccine. This, the team explained, increases the odds that the mice's immune systems will be able to produce antibodies against a variety of strains of HIV in the case of a future injection. And the benefits of the dual-adjuvant tactic is not just limited to fighting HIV. "This approach is compatible with many protein-based vaccines, so it offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks," said Love. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about HIV? Let us know via health@ Reference Rodrigues, K. A., Zhang, Y. J., Lam, J., Aung, A., Morgan, D. M., Romanov, A., Maiorino, L., Yousefpour, P., Gibson, G., Ozorowski, G., Gregory, J. R., Amlashi, P., Van, R., Buckley, M., Ward, A. B., Schief, W. R., Love, J. C., & Irvine, D. J. (2025). Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion. Science Translational Medicine, 17(803).

Biodefense Market Size worth $22.8 billion, Globally, by 2030 with 5% CAGR - Exclusive Study by The Research Insights
Biodefense Market Size worth $22.8 billion, Globally, by 2030 with 5% CAGR - Exclusive Study by The Research Insights

Yahoo

time2 hours ago

  • Yahoo

Biodefense Market Size worth $22.8 billion, Globally, by 2030 with 5% CAGR - Exclusive Study by The Research Insights

CHICAGO, June 19, 2025 /PRNewswire/ -- The global biodefense market size is projected to be valued at USD 16.1 billion in 2023 and reach USD 22.8 billion by 2030, growing at a CAGR of 5.0% according to a new report by The Research Insights. The biodefense market has experienced significant expansion recently due to the rising critical threat posed by emerging infectious diseases. The rapid impact of pandemics such as COVID-19, Ebola, and Monkeypox has shown how diseases can quickly cause healthcare system failures and lead to economic and social disruptions. Current health crises prove the necessity of having strong preparedness and resilience systems to manage biological hazards from natural occurrences and human-made threats. Global governments and health organizations have increased their biodefense system efforts in response to recent events. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the biodefense market growth of 5.0% comprises product, application, end use and geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Biodefense Market Share, Download FREE Sample Pages: Market Overview and Growth Trajectory: Biodefense Market Growth: According to an exhaustive report by The Research Insights, the Biodefense Market is undergoing significant growth, driven by the rising focus on dual-use technologies which provide benefits for both military and national security applications as well as public health initiatives. The COVID-19 pandemic highlighted that technologies designed for biodefense purposes can be adapted rapidly for pandemic preparedness and the reverse is also true. The biodefense market is increasingly recognizing that investing in technologies with dual applications creates a win-win scenario: National administrations expand their biodefense strength at the same time they boost public health resilience. Next-Gen Science Fortifies Global Shields Against Biological Threats: As global health and security rapidly change today, biodefense market capabilities are being transformed by technological advancements. Technological advances in synthetic biology and genomic surveillance along with rapid diagnostics and vaccine development platforms now provide nations with advanced capabilities to quickly identify, stop, and address biological threats precisely. Using synthetic biology scientists can quickly modify microorganisms to create specific vaccines and treatments after identifying new pathogens. The swift creation of mRNA vaccines during the COVID-19 pandemic established a new standard for rapid vaccine development. Current technological advances offer improved preparedness for both upcoming pandemics and bioterror attacks. The practice of genomic surveillance stands as a pivotal development because its capabilities allow scientists to detect unusual microbial activity or new pathogens early on. The integration of AI-powered analytics with this capability allows for the prediction of outbreaks before they worsen which enables governments to take early action rather than waiting to respond. These technologies go beyond simple technical enhancements to illustrate a fundamental change in approach. The biodefense industry is transitioning from outdated reactive approaches to advanced tech-driven ecosystems that respond instantly to changes. The world is developing smarter security systems through innovation to protect against biological attacks and maintain public health in today's complex and unpredictable global environment. For Detailed Market Insights, Visit: Bioterrorism Fears Ignite Urgent Global Race for Biodefense Preparedness: As warfare boundaries blur between traditional methods and unconventional dangers, bioterrorism emerges as a primary global threat. The threat of terrorist organizations creating weapons from deadly pathogens either found in nature or created in labs has become a more credible danger which motivates governments globally to respond rapidly and forcefully. Increased awareness about bioterrorism threats is leading to fast expansion in the biodefense market as countries work urgently to strengthen their public health systems and national security defenses. The accessibility of CRISPR and synthetic biology tools has transformed intentional outbreak risks into real national security threats. Governments are increasing their spending on early-warning systems and biosurveillance networks while building emergency vaccine and treatment stockpiles to combat biological threats. The biodefense market sees increasing R&D efforts towards developing rapid-response platforms designed to swiftly detect and tackle new pathogens. Defense departments and biotech companies along with public health agencies are building more alliances to maintain an advantage over possible threats. Global Governments Step Up as First Responders in the Biodefense Race: Governments worldwide have become the primary support system for the biodefense market due to increasing biological threats including pandemics and potential bioterrorist attacks. Public sector agencies allocate substantial resources toward preparedness and research infrastructure because they understand that delayed responses to biological threats lead to uncontrollable crises. The U.S. Department of Defense (DoD) and the Biomedical Advanced Research and Development Authority (BARDA) have demonstrated strong commitment by investing billions of dollars in vaccine research and development along with rapid diagnostic tools and advanced digital therapeutics. Public-private partnerships that support biodefense readiness today have emerged alongside accelerated innovation through these targeted investments. The strategic investment in funding extends beyond emergency situations. Long-term research and development programs targeting emerging threats and dual-use technologies now receive expanded government support together with manufacturing resilience efforts. The biodefense market evolves into a dynamic and forward-looking domain through collaboration because stakeholders recognize that health security requires shared global responsibilities and starts with policy and public funding. Stay Updated on The Latest Biodefense Market Trends: Geographical Insights: The biodefense market is dominated by North America with the United States accounting for most of its share. Federal financial support combined with established programs and sophisticated biotechnology facilities drive regional advantages. The Department of Defense (DoD), Biomedical Advanced Research and Development Authority (BARDA), and Department of Homeland Security (DHS) prioritize biodefense within their national security strategies. The biodefense market in Europe continues to expand due to transnational health security programs and insights obtained from the COVID-19 pandemic. The European Union created the Health Emergency Preparedness and Response Authority (HERA) to manage biodefense tasks while supporting research development and maintaining a reserve of countermeasures. National laboratories along with disease surveillance systems and vaccine manufacturing facilities receive investments from Germany, France and the UK. The biodefense market in the Asia Pacific region is undergoing swift growth particularly in nations including China and Japan as well as South Korea and India. The outbreak of diseases such as SARS and H1N1 followed by COVID-19 drove important investments in biodefense measures. Biodefense Market Segmentation and Geographical Insights: Based on product, the biodefense market is divided into anthrax, smallpox, botulism, radiation/nuclear and others. The anthrax segment held the largest share of the biodefense market in 2024. Based on application, the biodefense market is divided into biological threat detection, medical countermeasures and decontamination. The medical countermeasures segment held the largest share of the biodefense market in 2024. Based on end use, the biodefense market is divided into government, military, healthcare and research institutions. The government segment accounted for a larger share of the biodefense market in 2024. The biodefense market is segmented into five major regions: North America; Europe; Asia Pacific; Latin America; Middle East & Africa. Purchase Premium Copy of Global Biodefense Market Size and Growth Report (2023-2030) at: Key Players and Competitive Landscape: The Biodefense Market is characterized by the presence of several major players, including: XOMA corporation Altimmune Inc. Emergent Biosolutions Inc. Dynavax Technologies Corporation. SIGA Technologies. Elusys Therapeutics Inc. Ichor Medical Systems. Dynport Vaccine Company. Cleveland Biolabs. Bavarian Nordic. Ology Bioservices. Alnylam Pharmaceuticals Inc These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. Biodefense Market Recent Developments and Innovations: In February 2025, Thermo Fisher Scientific (US) announced the acquisition of the Solventum (US) Purification and Filtration business for USD 1.5 billion in cash. This strategic acquisition will expand Thermo Fisher's bioproduction capabilities, particularly in filtration technologies essential for biologics manufacturing. In September 2024, Synexis (US) announced a strategic partnership with Diversey(US), a global leader in hygiene and infection prevention solutions, to expand the reach of its Dry Hydrogen Peroxide (DHP™) technology. In March 2024, Emergent BioSolutions Inc. (EBS), received United States Food and Drug Administration (FDA) approval for BioThrax, for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. For Region-Specific Market Data, Check Out Brief Sample Pages: Key Questions Addressed: 1. What is the key opportunity in the biodefense market?- Collaboration between government agencies and pharmaceutical/biotech companies offers scalable and responsive biodefense strategies. 2. What is the expected market size for biodefense market by 2030? - The expected market size for biodefense is USD 22.8 Billion in 2030. 3. Which are the major end use where biodefense is used?- Major end use includes government, military, healthcare and research institutions. 4. Which product segment for biodefense market has the potential to register the highest market share? - Anthrax segment for biodefense market is expected to register highest market share of 31% in 2024. 5. Which region is estimated to witness a high demand for biodefense over the forecast period? - Asia Pacific is estimated to witness a high demand for biodefense growing at a CAGR of 9.1% over the forecast period 6. Who are the key players in biodefense market?- The key players in the market are XOMA corporation, Altimmune Inc., Emergent Biosolutions Inc., Dynavax Technologies Corporation., SIGA Technologies., Elusys Therapeutics Inc., Ichor Medical Systems., Dynport Vaccine Company., Cleveland Biolabs., Bavarian Nordic., Ology Bioservices and Alnylam Pharmaceuticals Inc. Conclusion: The biodefense market experiences rapid global expansion because of rising bioterrorism threats alongside emerging infectious diseases and growing awareness of health security at national and global levels. The worldwide market landscape is evolving to adopt proactive technological approaches which include advancements in mRNA vaccine platforms, genomic surveillance technologies, synthetic biology, and AI-based biosurveillance systems to boost biodefense readiness. Dual-use technology advancements help connect pandemic response with national security efforts thus establishing biodefense as the cornerstone of modern public health systems. Despite ongoing obstacles like regulatory challenges and substantial development expenses combined with ethical concerns the need for globally coordinated and balanced solutions remains essential. The biodefense market will keep developing as a crucial multidisciplinary ecosystem spurred by innovation through international cooperation and steadfast government support due to increasing complexity in biological threats. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: The report from The Research Insights, therefore, provides several stakeholders—including raw material & technology providers, product developers & biotech manufacturers, government regulators, system integrators and end users —with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 22.8 billion by 2030, the Biodefense Market represents a significant opportunity for raw material & technology providers, product developers & biotech manufacturers, government regulators, system integrators, end-users, investors, industry stakeholders, and others. By staying abreast of market trends, embracing innovation, and focusing on quality and performance, companies can position themselves for success in this dynamic and evolving market landscape. Check out more related studies published by The Research Insights: mRNA Therapeutics Market - The global mRNA therapeutics market size is expected to reach USD 31.30 billion by 2030, according to a new report by The Research Insights. It is projected to register a CAGR of 17.05% during the forecast period, driven primarily by remarkable potential of mRNA-based therapeutics in addressing chronic diseases. Bio Decontamination Market - The global bio decontamination market size is expected to reach USD 396.49 million by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 8.62% from 2024 to 2030. This projected expansion can be attributed to several key factors, including the increasing number of surgical procedures, which heightens the risk of hospital-acquired infections (HAIs). Predictive Disease Analytics Market - The global predictive disease analytics market size is anticipated to reach USD 10.2 billion by 2030 and is projected to grow at a CAGR of 22.7% from 2023 to 2030, according to a new report by The Research Insights. The market is expected to experience substantial growth in the coming years, driven by its transformative potential in improving patient outcomes and streamlining healthcare delivery. Browse More related reports on Healthcare Market – About The Research Insights: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Press Release: Latest News: | Logo - View original content: SOURCE The Research Insights

RFK Jr. plans crackdown on pharma ads in threat to $10 billion market
RFK Jr. plans crackdown on pharma ads in threat to $10 billion market

American Military News

time2 hours ago

  • American Military News

RFK Jr. plans crackdown on pharma ads in threat to $10 billion market

The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending. Although the U.S. is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it's instead focusing on cutting down on the practice by adding legal and financial hurdles, according to people familiar with the plans who weren't authorized to speak publicly on the matter. The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad — likely making broadcast ads much longer and prohibitively expensive — or removing the industry's ability to deduct direct-to-consumer advertising as a business expense for tax purposes, these people said. The discussions are ongoing and plans could still change before the agency undertakes any action, they said. Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He's long wanted to more strictly regulate how medicines are promoted. He's said he believes Americans consume more drugs than people in other countries because of the U.S. drug companies' ability to directly advertise to consumers. The new policies could threaten a key source of revenue to advertising and media companies, as well as the U.S. pharmaceutical industry. Companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising in total, according to a report from the advertising data firm MediaRadar. AbbVie Inc. and Pfizer Inc. were particularly big spenders. AbbVie alone spent $2 billion on direct-to-consumer drug ads last year, primarily on advertising for the company's anti-inflammatory drugs Skyrizi and Rinvoq. The medicines brought in more than $5 billion for AbbVie in the first quarter of 2025. 'We are exploring ways to restore more rigorous oversight and improve the quality of information presented to American consumers,' HHS spokesperson Andrew Nixon said in a written statement, adding that no final decisions have been made. AbbVie shares fell as much as 2.3% on Tuesday, their biggest drop in a month. Pfizer shares slipped as much as 1.7%. Ad reversal Before the loosening of advertising regulations by the Food and Drug Administration in 1997, U.S. pharma companies had to list all possible side effects for a medication if they wanted to mention which condition the drug being advertised was intended to treat. Reading out a list of side effects took so long it drove up the cost for air time and meant there wasn't as much broadcast advertising as there is today, said Jim Potter, executive director of the Coalition for Healthcare Communication, a trade association. The FDA change allowed ads to disclose fewer side effects and also allowed companies to direct customers to talk to their doctors, call a telephone number, or visit a website to get more information on the advertised drugs. In the following years, TV pharma ad spending surged. In 2024, 59% of the pharmaceutical industry's spend was on television advertising, making pharma the third-highest spending industry on television ads, according to MediaRadar. If the Trump administration brings back some of those restrictions, broadcast ads may become more 'impractical,' according to Meredith Rosenthal, a professor of health economics and policy at Harvard University's school of public health, who has studied the impacts of pharma advertising. More specific drug ads could have benefits for patients who might be prompted to talk to their doctor for the first time about a medical condition like depression or erectile dysfunction, Rosenthal said. However, there are also drawbacks. Drug ads can be used to drive sales of expensive, brand-name medicines when lower-cost generic alternatives may be appropriate, she said. When asked if a crackdown on ads would hurt its business, AbbVie chief commercial officer Jeff Stewart told analysts at a conference in May that the company 'would have to pivot.' He said the company could shift its investment to 'disease awareness' or through advertising on digital channels rather than through mass media. Tax changes The Trump administration could also work with Congress to prohibit pharmaceutical companies from deducting direct-to-consumer advertising costs as business expenses on their taxes. House lawmakers discussed the idea in talks over President Donald Trump's tax cut legislation, but ultimately left the measure out of the bill. The Senate omitted it as well. HHS has been supportive of those discussions, according to a person familiar with the talks. Kennedy has also said publicly he's having conversations about tax changes within the administration, telling Senator Josh Hawley during a May hearing on Capitol Hill that he expected an announcement on the matter 'within the next few weeks.' Joe Grogan, who served as White House Domestic Policy Council chief during President Donald Trump's first term and now consults for health-care companies, said it's unclear whether lawmakers will have an appetite to crack down on the pharmaceutical industry further given Trump's tariff threats and demands to dramatically lower drug prices. Meanwhile, the pharmaceutical industry has warned that allowing lawmakers to regulate advertising by changing the tax code to single out pharmaceutical companies could set a dangerous precedent and raise the specter of lawsuits. Other industries also can deduct advertising costs as business expenses, heightening concerns they could be targeted next. 'If you choose a sector, if one becomes a target, everyone becomes a target,' said Potter of the Coalition for Healthcare Communication. The National Association of Broadcasters, which represents companies that own radio and television stations, said the group opposes restrictions on direct-to-consumer advertising, and that revenue from ads allows local broadcasters to staff newsrooms and invest in weather technology. 'Restricting pharmaceutical ads would have serious consequences for stations, particularly those in smaller markets, and could raise First Amendment concerns,' NAB spokesperson Alex Siciliano said. ___ © 2025 Bloomberg L.P. Distributed by Tribune Content Agency, LLC.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store